FONR vs. RMTI, EDAP, CUTR, BFLY, NNOX, TMCI, CLPT, SGHT, TCMD, and SMTI
Should you be buying FONAR stock or one of its competitors? The main competitors of FONAR include Rockwell Medical (RMTI), Edap Tms (EDAP), Cutera (CUTR), Butterfly Network (BFLY), Nano-X Imaging (NNOX), Treace Medical Concepts (TMCI), ClearPoint Neuro (CLPT), Sight Sciences (SGHT), Tactile Systems Technology (TCMD), and Sanara MedTech (SMTI).
Rockwell Medical (NASDAQ:RMTI) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.
FONAR has a net margin of 10.66% compared to Rockwell Medical's net margin of -5.06%. FONAR's return on equity of 7.50% beat Rockwell Medical's return on equity.
Rockwell Medical has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
In the previous week, Rockwell Medical had 4 more articles in the media than FONAR. MarketBeat recorded 7 mentions for Rockwell Medical and 3 mentions for FONAR. FONAR's average media sentiment score of 1.54 beat Rockwell Medical's score of 0.70 indicating that FONAR is being referred to more favorably in the news media.
FONAR has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than FONAR, indicating that it is currently the more affordable of the two stocks.
Rockwell Medical presently has a consensus target price of $7.00, indicating a potential upside of 66.67%. Given Rockwell Medical's higher possible upside, equities research analysts plainly believe Rockwell Medical is more favorable than FONAR.
Rockwell Medical received 130 more outperform votes than FONAR when rated by MarketBeat users. However, 74.15% of users gave FONAR an outperform vote while only 57.44% of users gave Rockwell Medical an outperform vote.
23.3% of Rockwell Medical shares are owned by institutional investors. Comparatively, 50.6% of FONAR shares are owned by institutional investors. 1.9% of Rockwell Medical shares are owned by company insiders. Comparatively, 2.2% of FONAR shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
FONAR beats Rockwell Medical on 11 of the 17 factors compared between the two stocks.
Get FONAR News Delivered to You Automatically
Sign up to receive the latest news and ratings for FONR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FONR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
Free FONR Stock Alerts